Marshall E Kadin, MD, John Morgan, PhD, Wei Wei, PhD, Zhihui Song, PhD, Yibin Yang, PhD
Aesthetic Surgery Journal, Volume 43, Issue 2, February 2023, Pages 137–146
Background: Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is a rare, usually indolent CD30+ T-cell lymphoma with tumor cells, often surrounded by eosinophils, expressing IL-13 and pSTAT6.
Objectives: The aim of this study was to understand the unique tumor pathology and growth regulation of BIA-ALCL, leading to potential targeted therapies.
>> View on the Aesthetic Surgery Journal Website
|
Neha Akkad, MD, Rohan Kodgule, MD, Eric J Duncavage, MD, Neha Mehta-Shah, MD, MSCI, David H Spencer, MD, PhD, Marcus Watkins, PhD, Cara Shirai, PhD, Terence M Myckatyn, MD, FACS, FRCSC
Aesthetic Surgery Journal, sjac282
Background: Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is a rare malignancy originating from the periprosthetic capsule of a textured, most often macrotextured, breast implant. Identified in women whose indications for breast implants can be either aesthetic or reconstructive, the genomic underpinnings of this disease are only beginning to be elucidated.
Objectives: The aim of this study was to evaluate the exomes, and in some cases the entire genome, of patients with BIA-ALCL. Specific attention was paid to copy number alterations, chromosomal translocations, and other genomic abnormalities overrepresented in patients with BIA-ALCL.
>> View on the Aesthetic Surgery Journal Website |
|
|
“…patients come to me seeking answers about new technologies and looking to receive effective treatments.”
